FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095982273> ?p ?o ?g. }

• W3095982273 endingPage "6022" @default.
• W3095982273 startingPage "6016" @default.
• W3095982273 abstract "Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib in patients with advanced NSCLC.A retrospective study was conducted on 150 patients with advanced NSCLC who were treated with anlotinib and discontinued treatment after disease progression or intolerance due to adverse events. Progression-free survival (PFS) of advanced NSCLC patients served as an endpoint. Kaplan-Meier survival curves were applied to evaluate the short-term efficacy of anlotinib treatment in advanced NSCLC patients.The median PFS of the whole 150-patient cohort was 5.0 months in (95% CI: 4.00-5.95), 5.0 months (95% CI: 3.0-6.00) in 90 patients with adenocarcinoma, and 4.5 months (95% CI: 4.00-7.00) in 60 patients with squamous cell carcinoma (P=0.676). The PFS was 6.5 months (95% CI: 4.00-8.80) and 4.5 months (95% CI: 4.00-5.60) in the first-/second-line and ≥ third-line patients, respectively (P=0.315). Following the Eastern Cooperative Oncology Group performance status (ECOG PS) score, the median PFS of 95 patients with a PS score 0-1 was 5.5 months (95% CI: 4.50-6.50), and the median PFS of 55 patients with a PS score ntswas 4.0 months (95% CI: 3.00-5.00) (P=0.221). For the 49 patients in the combination group the median PFS was 7.0 months (95% CI: 4.00-9.00), while that of the 101 patients in the anlotinib-alone group was 4.0 months in (95% CI: 2.80-5.50) (P=0.010). In a separate analysis of the combination group, the median PFS of anlotinib combined with chemotherapy, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), and immunotherapy was 5.5 months (95% CI: 4.00-9.00), 12.0 months (95% CI: 6.00-12.00), and 6.5 months (95% CI: 4.00-9.80), respectively (P=0.036).Anlotinib exhibits good tolerance and performance in prolonging the PFS of patients and has considerable potential as a treatment for advanced NSCLC." @default.
• W3095982273 created "2020-11-09" @default.
• W3095982273 creator A5005478064 @default.
• W3095982273 creator A5027049854 @default.
• W3095982273 creator A5030677018 @default.
• W3095982273 creator A5052729067 @default.
• W3095982273 creator A5075508791 @default.
• W3095982273 creator A5075758338 @default.
• W3095982273 date "2020-10-01" @default.
• W3095982273 modified "2023-10-14" @default.
• W3095982273 title "Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer" @default.
• W3095982273 cites W1868293759 @default.
• W3095982273 cites W2054841768 @default.
• W3095982273 cites W2079332722 @default.
• W3095982273 cites W2160982674 @default.
• W3095982273 cites W2180834360 @default.
• W3095982273 cites W2272984102 @default.
• W3095982273 cites W2528424364 @default.
• W3095982273 cites W2791667474 @default.
• W3095982273 cites W2793605704 @default.
• W3095982273 cites W2798239149 @default.
• W3095982273 cites W2885503610 @default.
• W3095982273 cites W2902112970 @default.
• W3095982273 cites W2972602672 @default.
• W3095982273 cites W2981634585 @default.
• W3095982273 cites W2992802618 @default.
• W3095982273 cites W4240457516 @default.
• W3095982273 doi "https://doi.org/10.21037/jtd-20-2855" @default.
• W3095982273 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7656407" @default.
• W3095982273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33209434" @default.
• W3095982273 hasPublicationYear "2020" @default.
• W3095982273 type Work @default.
• W3095982273 sameAs 3095982273 @default.
• W3095982273 citedByCount "7" @default.
• W3095982273 countsByYear W30959822732021 @default.
• W3095982273 countsByYear W30959822732022 @default.
• W3095982273 crossrefType "journal-article" @default.
• W3095982273 hasAuthorship W3095982273A5005478064 @default.
• W3095982273 hasAuthorship W3095982273A5027049854 @default.
• W3095982273 hasAuthorship W3095982273A5030677018 @default.
• W3095982273 hasAuthorship W3095982273A5052729067 @default.
• W3095982273 hasAuthorship W3095982273A5075508791 @default.
• W3095982273 hasAuthorship W3095982273A5075758338 @default.
• W3095982273 hasBestOaLocation W30959822731 @default.
• W3095982273 hasConcept C120665830 @default.
• W3095982273 hasConcept C121332964 @default.
• W3095982273 hasConcept C121608353 @default.
• W3095982273 hasConcept C126322002 @default.
• W3095982273 hasConcept C143998085 @default.
• W3095982273 hasConcept C167135981 @default.
• W3095982273 hasConcept C197934379 @default.
• W3095982273 hasConcept C203092338 @default.
• W3095982273 hasConcept C2776256026 @default.
• W3095982273 hasConcept C2776694085 @default.
• W3095982273 hasConcept C2780739268 @default.
• W3095982273 hasConcept C2781182431 @default.
• W3095982273 hasConcept C535046627 @default.
• W3095982273 hasConcept C61511704 @default.
• W3095982273 hasConcept C71924100 @default.
• W3095982273 hasConcept C72563966 @default.
• W3095982273 hasConceptScore W3095982273C120665830 @default.
• W3095982273 hasConceptScore W3095982273C121332964 @default.
• W3095982273 hasConceptScore W3095982273C121608353 @default.
• W3095982273 hasConceptScore W3095982273C126322002 @default.
• W3095982273 hasConceptScore W3095982273C143998085 @default.
• W3095982273 hasConceptScore W3095982273C167135981 @default.
• W3095982273 hasConceptScore W3095982273C197934379 @default.
• W3095982273 hasConceptScore W3095982273C203092338 @default.
• W3095982273 hasConceptScore W3095982273C2776256026 @default.
• W3095982273 hasConceptScore W3095982273C2776694085 @default.
• W3095982273 hasConceptScore W3095982273C2780739268 @default.
• W3095982273 hasConceptScore W3095982273C2781182431 @default.
• W3095982273 hasConceptScore W3095982273C535046627 @default.
• W3095982273 hasConceptScore W3095982273C61511704 @default.
• W3095982273 hasConceptScore W3095982273C71924100 @default.
• W3095982273 hasConceptScore W3095982273C72563966 @default.
• W3095982273 hasIssue "10" @default.
• W3095982273 hasLocation W30959822731 @default.
• W3095982273 hasLocation W30959822732 @default.
• W3095982273 hasLocation W30959822733 @default.
• W3095982273 hasOpenAccess W3095982273 @default.
• W3095982273 hasPrimaryLocation W30959822731 @default.
• W3095982273 hasRelatedWork W2010956031 @default.
• W3095982273 hasRelatedWork W2040381674 @default.
• W3095982273 hasRelatedWork W2044789494 @default.
• W3095982273 hasRelatedWork W2131562451 @default.
• W3095982273 hasRelatedWork W2351757746 @default.
• W3095982273 hasRelatedWork W2362760700 @default.
• W3095982273 hasRelatedWork W2374478765 @default.
• W3095982273 hasRelatedWork W2419208358 @default.
• W3095982273 hasRelatedWork W2902679640 @default.
• W3095982273 hasRelatedWork W2943977880 @default.
• W3095982273 hasVolume "12" @default.
• W3095982273 isParatext "false" @default.
• W3095982273 isRetracted "false" @default.
• W3095982273 magId "3095982273" @default.
• W3095982273 workType "article" @default.